Molecular and cellular biology of von Willebrand factor by Lyons, Susan E. & Ginsburg, David W.
Ohya Y, Goebl M, Goodman LE, Petersen- 
Bjom S, Friesen DJ: 1991. Yeast CAL1 is a 
structural and functional homologue to the 
DPRl (RAM) gene involved in ras process- 
ing. J Biol Chem 266:12,356-12,360. 
Ransnas LA, Insel PA: 1989. Subunit disso- 
ciation is the mechanism for hormonal 
activation of the G, protein in native mem- 
branes. Proc Nat1 Acad Sci USA 86:7900- 
7903. 
Reese JH, Maltese WA: 1991. Post-transla- 
tional modification of proteins by 15- 
carbon and 20-carbon isoprenoids in three 
mammalian cell lines. Mol Cell Biochem 
104:109-116. 
Resh MD, Ling H-P: 1990. Identification of 
a 32K plasma membrane protein that binds 
to the myristylated amino-terminal sequence 
of ~60”-~~. Nature 34684-86. 
Rossi G, Jiang Y, Newman AP, Ferro- 
Novick S: 1991. Dependence of YPTl and 
SEC4 membrane attachment on Bet2. Na- 
ture 351:158-161. 
Seabra MC, Reiss Y, Casey PJ, Brown MS, 
Goldstein JL: 199 1. Protein famesyltrans- 
ferase and geranylgeranyltransferase share 
a common a subunit. Cell 65:429-434. 
Seabra MC, Goldstein JL, Sudhof TC, 
Brown MS: 1992a. Rab geranylgeranyltrans- 
ferase: a multisubunit enzyme that prenyl- 
ates GTP-binding proteins terminating in 
Cys-X-Cys or CysCys. J Biol Chem 267: 
14,497-14,503. 
Seabra MC, Brown MS, Slaughter CA, 
Sudhof TC, Goldstein JL: 1992b. Purifica- 
tion of component A of rab geranylger- 
anyltransferase: possible identity with the 
choroideremia gene product. Cell 70: 1049- 
1057. 
Seabra MC, Brown MS, Goldstein JL: 1993. 
Retinal degeneration in choroideremia: de- 
ficiency of rab geranylgeranyltransferase. 
Science 259~377-381. 
Sewell JL, Kahn RA 1988. Sequences of the 
bovine and yeast ADP-ribosylation factor 
and comparison to other GTP-binding pro- 
teins. Proc Nat1 Acad Sci USA 85:4620- 
4624. 
Simon MI, Strathman MP, Gautam N: 
1991. Diversity of G proteins in signal 
transduction. Science 252:802-808. 
Spiegel AM, Backlund JS Jr, Butrynski JE, 
Jones TLZ, Simonds WF: 1991. The G 
protein connection: molecular basis of mem- 
brane association. Trends Biochem Sci 
16:338-341. 
Stemweis PC: 1986. The purified a subunits 
of Go and Gi from bovine brain require fky 
for association with phospholipid vesicles. J 
Biol Chem 261:631-637. 
Tang W-T, Gilman AG: 1991. Type-specific 
regulation of adenyl cyclase by G protein & 
subunits. Science 254:1500-1503. TCM 
34 
Molecular and Cellular Biology of 
Von Willebrand Factor 
Susan E. Lyons and David Ginsburg 
Von Willebrand factor (vWF), a central protein in the regulation of 
blood coagulation, serves as a major adhesive link between platelets and 
the blood vessel wall and also functions as a carrier in plasma for factor 
VIII. Abnormalities of vWF result in von Willebrand disease (vWD), a 
common inherited human bleeding disorder. Deficient von Willebrand 
factor function has been proposed as potentially protective against the 
development of coronary vascular disease and several recent investiga- 
tional therapies are directed at the vWF-platelet interaction. This review 
summarizes the current state of knowledge regarding the biosynthesis 
and processing of vWF and the relationship of vWF structure to 
function. Finally, recent progress in identifying specific genetic muta- 
tions responsible for the many variants of vWD is discussed. (Trends 
Cardiovasc Med 1994;4;34-39) 
Von Willebrand factor (vWF), a multi- 
merit plasma glycoprotein, plays a cen- 
tral role in hemostasis. vWF mediates 
initial platelet adhesion to the subendo- 
thelium after vascular injury. In addi- 
tion, vWF carries factor VIII in the 
circulation and is required for factor VIII 
stability in plasma (Figure 1). vWF is 
synthesized from an 8.7~kilobase (kb) 
mRNA and is expressed exclusively in 
endothelial cells and megakaryocytes. 
The vWF gene contains 52 exons, span- 
ning 178 kb on chromosome 12. A partial 
unprocessed pseudogene, duplicating 
exons 23-34, is present on chromosome 
22 (Sadler 1991, Ginsburg and Bowie 
1992) (Figure 2). 
In 1926, Erik von Willebrand first 
described a severe bleeding disorder in a 
family on an island of the Aland archi- 
pelago. The autosomal dominant inheri- 
tance pattern of the disease, later named 
von Willebrand disease (vWD), clearly 
Susan E. Lyons and David Ginsburg are at the 
Howard Hughes Medical Institute, Depart- 
ments of Human Genetics and Internal Medi- 
cine, and Program of Cellular and Molecular 
Biology, University of Michigan Medical 
School, Arm Arbor, MI 48109-0650, USA. 
01994, Elsevier Science Inc., 1050-1738/94/$7.00 
showed that it was distinct from hemo- 
philia A, an X-linked bleeding disorder 
caused by defects in factor VIII. In 197 1, 
vWF was immunologically distinguished 
from the factor VIII and, in 1985, the 
vWF cDNA was cloned from endothelial 
cell cDNA libraries and confirmed by 
amino acid sequencing (Ginsburg and 
Bowie 1992). Since that time, a great 
deal has been learned about vWF’s struc- 
ture, function, and the defects that result 
in vWD. 
l Von Willebrand Factor Biosynthesis 
Synthesis of vWF is a complex multistep 
process. The vWF primary translation 
product is a 2813-amino-acid pre-pro- 
polypeptide with a 22-amino-acid classic 
signal sequence that is cleaved cotransla- 
tionally (Figure 2). The 741-amino-acid 
propeptide is removed at a later step, 
leaving a 205@amino-acid mature vWF 
protein. Posttranslational processing of 
vWF includes dimerization, glycosyla- 
tion, sulfation, propeptide cleavage, and 
multimerization, followed by storage or 
secretion (Figure 3). Characterization of 
these biosynthetic steps in megakar- 
yocytes and cultured endothelial cells 
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has shown that N-linked carbohydrates 
are added in high-mannose form in the 
endoplasmic reticulum (ER) and are 
further processed to complex forms in 
the Golgi apparatus (Wagner 1990). O- 
glycosylation and sulfation of some N- 
linked oligosaccharides also occur in 
Golgi compartments. vWF molecules 
dimerize within the ER via disulfide 
bond formation at the carboxyl-terminal 
end. The propeptide is cleaved in Golgi 
and post-Golgi compartments and disul- 
fide linkages are formed at the amino 
termini to generate high-molecular- 
weight (HMW) multimers consisting of 
up to 100 subunits. vWF is the only 
protein known to form disulfide-linked 
multimers in a compartment past the 
ER. In cultured endothelial cells, weak 
base inhibits multimerization of dimers, 
and acidic pH is required in cell-free 
synthesis, suggesting that multimeriza- 
tion occurs in an acidic cellular environ- 
ment. These data suggest that an active 
catalytic process may be involved in 
disulfide bonding of dimers, since spon- 
taneous oxidation of free sulfhydryls 
would be optimal at basic, not acidic pH 
(Wagner 1990). 
vWF is secreted via constitutive and 
regulated pathways. In cultured endo- 
thelial cells, 95% of vWF synthesized is 
secreted constitutively, while the remain- 
ing 5% is packaged in specialized storage 
granules termed Weibel-Palade bodies 
(Wagner 1990). Similar granules ob- 
served in platelets are termed a granules. 
In electron-microscopic studies, these 
granules appear as rodlike structures 0.1 
lrn wide and up to 4 km long. Tubular 
structures seen inside the granules are 
hypothesized to be vWF multimers. Re- 
cently, a transmembrane receptor, P 
selectin, also known as GMP140, 
PADGEM, or CD62, was found to colo- 
calize with vWF to Weibel-Palade bodies 
and a granules (Bonfanti et al. 1989). 
In vivo, plasma vWF levels rise rapidly 
after administration of epinephrine, vaso- 
pressin, nicotinic acid, or the vasopressin 
analogue, 1 -desamino-8-D-arginine-vaso- 
pressin (DDAVP). These agents appear to 
cause release of vWF from storage pools, 
though they do not stimulate vWF secre- 
tion from endothelial cells in vitro. In 
cultured endothelial cells, the release of 
vWF from storage granules can be stimu- 
lated with various secretagogues, includ- 
ing the calcium ionophore A23 187. phor- 
bol myristate acetate (PMA), thrombin, 
multimeric vWF 
Figure 1. Von Willebrand factor (vWF) function; vWF monomers are indicated as red circles. 
Multimeric vWF is seen to be stored within the Weibel-Palade body of the endothelial cell and 
in the granule precursor of the megakaryocyte, subsequently giving rise to the platelet a 
granule. vWF is shown bound to the platelet surface and to the subendothelium, serving a 
critical adhesive bridging function. The plasma complex of multimeric vWF with factor VIII 
also acts to localize factor VIII to the site of clot formation. 
fibrin, histamine, and complement pro- tive in mediating platelet-binding func- 
teins C5b-9 (Wagner 1990). Thrombin tions, may play a role in the rapid 
and fibrin are present at sites of vascular response to vascular injury. 
injury, while histamine and complement 
factors are localized to areas of inflam- 
mation. The storage granules have been 
l Von Willebrand Factor Expression 
shown to contain larger multimeric vWF 
in Heterologous Cells 
species than the constitutively secreted Cloning of the cDNA for vWF has ena- 
pool (Sporn et al. 1986). Release of these bled study of vWF biosynthesis in heteml- 
larger multimers, which are most effec- ogous cells. vWF has been expressed by 
Figure 2. Schematic of the human von Willebrand factor (vWF) gene, structural features of 
pre-pro-vWF, and functional domains within the mature vWF protein: the vWF gene and 
pseudogene are shown at the top, with blue boxes representing exons and the line representing 
introns. The vWF primary translation product, pre-pro-vWF, is depicted in the middle. The 
location of signal peptide (sp) and propeptide (pro) cleavage sites are indicated by arrowheads, 
and repeated domains are labeled with letters, A-D. Regions containing clustered mutations 
responsible for factor-VIII @VIII)-binding defects, type-IIB von Willebrand disease (vWD), and 
type-IIA vWD are indicated. At the bottom of the panel, the locations of vWF functional 
domains within the mature vWF protein are shown, with amino acid numbers for mature vWF 
indicated below. Adapted from Ginsburg and Bowie (1992), with permission. 
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Figure 3. Posttranslational processing of von Willebrand factor (vWF): the processing and 
assembly of vWF is illustrated schematically here. The sequential occurrence of each step 
within discrete intracellular compartments is summarized at the top of the figure. 
Dimerlzation of pro-vWF monomers via disulfide formation at the C termini is shown at the 
bottom, with subsequent multimerization via interactions at the N termini within the Golgi 
and later compartments. From Ruggeri et al. (1994), with permission. 
transient and stable transfection in a 
variety of cell types. In most cases, vWF 
is secreted as HMW multimers, pro-vWF 
is correctly cleaved to the mature form 
though less efficiently than in endothe- 
lial cells, and the recombinant vWF 
appears to function comparably to endo- 
thelial vWF in platelet- and collagen- 
binding assays (Bonthron et al. 1986, 
Meulien et al. 1992, Verweij et al. 1987, 
Wise et al. 1988). Although the vWF 
molecule itself appears to specify the 
information needed for most of the steps 
in vWF synthesis in heterologous cells, 
only secretory cell lines exhibit regulated 
secretion of vWF, suggesting that the 
specialized cellular machinery for stor- 
age is required for vWF transport to 
secretory granules (Wagner et al. 1991). 
The 74 1 -amino-acid vWF propolypep- 
tide has been shown to be required for 
multimer assembly. When COS cells 
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were transfected with vWF cDNA lack- 
ing the sequence for the propolypeptide, 
only dimers were formed (Verweij et al. 
1987, Wise et al. 1988). Therefore, the 
propeptide is not required for dimeriza- 
tion, but is essential for further multi- 
merization. Studies by Verwiej et al. 
(1988) and by Wise et al. (1988) showed 
that an uncleavable pro-vWF species 
formed normal multimers in COS cells. 
Surprisingly, the propolypeptide could 
be present in truns and still direct mul- 
timer assembly (Wise et al. 1988). 
Cotransfection of the cDNA for the ma- 
ture vWF protein with the cDNA for the 
propeptide on a separate plasmid re- 
sulted in secretion of vWF multimers 
indistinguishable from multimers se- 
creted by cells transfected with the full- 
length vWF cDNA. In a cell-free system, 
multimerization of dimers also required 
the propeptide, consistent with results in 
COS cells. In this system, however, the 
propeptide was required in cis with the 
mature vWF sequence in order for mul- 
timer assembly to proceed (Mayadas and 
Wagner 1989). Recently, Mayadas and 
Wagner ( 1992) proposed a disulfide isom- 
erase activity for the propolypeptide. 
Protein disulfide isomerases are found in 
the ER, where folding and oligomeriza- 
tion typically take place; thus, the pres- 
ence of a disulfide isomerase activity 
within vWF would provide a mechanism 
for vWF multimerization in a post-ER 
compartment. In addition, a role for the 
vWF propeptide in targeting pro-vWF to 
the storage granule has been proposed 
(Wagner et al. 1991). A proprotein- 
processing enzyme termed PACE or furin, 
that cleaves pro-vWF at the correct cleav- 
age site, has recently been identified 
(Wise et al. 1990). 
l Von Willebrand Factor Function 
vWF-Factor VIII Interaction 
vWF forms a complex with factor VIII in 
plasma through electrostatic and hydro- 
phobic interactions. vWF protects factor 
VIII from degradation and may also 
serve to localize factor VIII to the site of 
a clot. Activation of factor VIII by throm- 
bin results in dissociation of the vWF- 
factor VIII complex, allowing activated 
factor VIII to perform as a cofactor in 
activation of factor X by factor IXa, and 
also rendering it susceptible to degrada- 
tion by activated protein C (Kaufman 
1992). The domain(s) on vWF responsi- 
ble for binding to factor VIII has been 
localized to the first 272 amino acids of 
vWF (Sadler 1991, Ruggeri et al. 1994). 
Propeptide cleavage appears to be re- 
quired for factor VIII binding, though 
the exact role of the propeptide in forma- 
tion of the factor-VIII-binding site is 
controversial (Leyte et al. 199 1, Wise et 
al. 1991, Kaufman 1992). 
While the concentration of vWF in 
plasma is 10 @mL and factor VIII in 
plasma is only 0.2 pg/mL, vWF appears 
to be saturated with factor VIII at a 
molar ratio of approximately 50: 1 (vWF 
to factor VIII). This saturation of vWF 
with factor VIII may explain the observa- 
tion that decreases in plasma vWF are 
generally accompanied by correspond- 
ing decreases in factor VIII levels. Thus, 
in severe forms of vWD, the clinical 
picture often has characteristics both of 
a platelet disorder and of hemophilia A 
(Sadler 199 1, Ginsburg and Bowie 1992). 
Role of vWF in Adhesion to the 
Subendothelium 
vWF is required for platelet adhesion at 
sites of vascular injury. When vessel wall 
subendothelium is exposed, vWF binds 
to the subendothelial matrix and to 
platelets, promoting platelet aggregation 
and formation of a platelet plug. Consti- 
tutively secreted vWF is found both 
distributed in the basement membrane 
and free in plasma. An additional pool of 
higher-molecular-weight vWF is present 
in the storage granules of the platelet and 
endothelial cell and can be released in 
response to vessel wall injury. The larg- 
est vWF multimers have higher affinity 
for binding to cell matrix than do the 
smaller vWF multimeric species (Rug- 
geri et al. 1994). 
The components of the subendothelial 
matrix involved in the binding of vWF 
have not been conclusively identified. In 
vitro, vWF has been shown to bind colla- 
gen types I, III, and VI, heparin, and 
sulfatides. However, antibody studies and 
treatment of endothelial matrix with col- 
lagenase, or growth of extracellular ma- 
trix in the presence of the collagen synthe- 
sis inhibitor, a,a’-dipyridyl, suggest that 
the fibrillar collagens (types I and III) are 
not necessary for vWF subendothelial 
binding (Ruggeri et al. 1994). Collagen VI, 
which is resistant to collagenase and 
a,a’-dipyridyl, remains a potential ligand 
for vWF in the matrix (Rand et al. 1991). 
Role of vWF in Platelet Adhesion 
and Aggregation 
Platelets adhere to vWF through two 
distinct receptors, GpIb/M and GpIIb/ 
IIIa. Unlike the factor VIII interaction 
with vWF, platelet binding depends on 
multimeric size. HMW vWF multimers 
bind platelets at both receptors with 
much higher affinity than the lower- 
molecular-weight forms (Gralnick et al. 
1981). In vitro, platelet adhesion medi- 
ated by vWF is highly shear rate depend- 
ent. At low shear rates, platelet adhesion 
to subendothelium can take place even 
in the absence of vWF. However, at high 
shear rates, simulating the environment 
in the microvasculature, vWF function 
becomes essential (Weiss et al. 1989, 
Ruggeri et al. 1994). 
Circulating vWF does not bind to 
resting platelets in normal hemostasis. 
Upon exposure of vessel subendothelial 
matrix, vWF binds matrix components 
and then gains the ability to bind the 
platelet receptor GpIb (Wagner 1990, 
Ruggeri et al. 1994). These results sug- 
gest either that vWF undergoes a confor- 
mational change after matrix binding 
that enables it to bind to GpIb, or that, 
alternatively, a high local concentration 
of vWF is required for platelet GpIb 
binding to occur. Experimentally, plasma 
vWF can bind to platelet GpIb after 
removal of sialic acid residues from the 
vWF molecule (Gralnick et al. 1985), or 
by the addition of the antibiotic risto- 
cetin or the snake-venom protein, botro- 
cetin (Ruggeri et al. 1994). These altera- 
tions may in some ways imitate the 
changes that occur through vWF binding 
to subendothelium in vivo, but to date 
these effects are not well understood. 
Since the botrocetin-binding site on vWF 
is in the same region as binding sites for 
the subendothelial matrix components, 
collagen and heparin, and the GpIb 
binding site, it is hypothesized that the 
formation of the botrocetin-vWF com- 
plex mimics the conformational changes 
that are normally brought about through 
vWF interaction with the subendothe- 
lium. 
The platelet GpIIb/IIIa receptor only 
becomes available for vWF binding after 
platelet activation. Platelets are activated 
at sites of vascular injury by a variety of 
agonists. In addition, binding of vWF to 
the platelet GpIb receptor appears to 
activate platelets, making the GpIIb/IIIa 
receptor available for ligand binding 
(Savage et al. 1992). GpIIb/IIIa is a 
member of the integrin family of adhe- 
sive proteins, which bind the consensus 
site RGD. An RGD sequence near the C 
terminus of vWF appears to be responsi- 
ble for vWF binding to GpIIb/IIIa 
(Beacham et al. 1992). Other adhesive 
proteins, including fibrinogen, throm- 
bospondin, fibronectin, and vitronectin, 
also contain RGD sites and may compete 
with vWF for binding to the GpIIb/IIIa 
receptor. The RGD site on subendothe- 
lial matrix vWF may also contribute to 
endothelial cell attachment to the vessel 
wall. 
The Central Role of vWF in Thrombosis 
and Hemostasis 
The central functional role of vWF in 
hemostasis is illustrated in Figure 1. 
Through distinct binding domains for 
discrete receptors on the platelet surface 
and other receptors within the subendo- 
thelium, vWF performs a bridging func- 
tion, binding the platelet to the vessel 
wall at sites of vascular injury. This 
appears to be one of the earliest events 
triggering formation of the initial plate- 
let plug. The unique multimeric struc- 
ture of vWF may be particularly impor- 
tant for its adhesive function by enabling 
multivalent interactions. By serving as 
the carrier for factor VIII, vWF may also 
coordinate formation of the fibrin blood 
clot at the site of a growing platelet 
thrombus. The critical role of vWF in 
coagulation is evident from the profound 
bleeding disorder that results from com- 
plete deficiency of vWF (see below). 
Indeed, patients with severe vWD suffer 
from both the immediate type of bleed- 
ing associated with loss of platelet func- 
tion as well as the often delayed visceral 
bleeding resulting from deficient fibrin 
clot formation, characteristic of classic 
hemophilia. The central position of vWF 
in clotting function has made it a target 
for a number of novel antithrombotic 
therapies centered on antibodies, pep- 
tides, or other compounds that inhibit 
vWF function (Ruggeri 1992). 
l Domain Structure of 
von Willebrand Factor 
vWF has a repeated structure, consisting 
of four types of domains A-D, shown in 
Figure 2 (Sadler 1991, Ginsburg and 
Bowie 1992). Each domain is repeated 
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2-5 times within the vWF polypeptide, 
accounting for -90% of the protein se- 
quence. The Al domain contains a num- 
ber of important functional regions, 
including binding sites for collagen, hep- 
arm, sulfatides, GpIb, and botrocetin. 
The A3 domain contains an additional 
collagen binding site. The Cl domain 
contains the RGD(S) sequence recog- 
nized by the integrins GpIIb/IIIa and the 
vitronectin receptor. Another RGD se- 
quence is present in the propeptide, but 
no role in integrin binding has been 
observed. Cysteine is the most common 
amino acid in vWF, comprising 8.3% of 
the vWF polypeptide. A total of 52 
disulfide bridges have been defined, all 
involved in intra- or intersubunit disul- 
fide bonds (Sadler 1991, Ginsburg and 
Bowie 1992, Ruggeri et al. 1994). 
l Von Willebraud Disease 
vWD encompasses a heterogeneous group 
of inherited defects in vWF. In epidemi- 
ologic studies in which populations are 
examined for laboratory abnormalities 
in vWF, a prevalence of vWD as high as 
1% has been reported (Rodeghiero et al, 
1987), though clinically significant vWD 
is probably observed less frequently in 
the population. Symptoms vary from 
mild to severe bleeding, and inheritance 
is generally autosomal dominant. A large 
number of vWD subtypes have been 
described, distinguished by subtle varia- 
tions in vWF activity and/or multimer 
pattern (Ginsburg and Bowie 1992, Bloom 
1991). The vast majority of vWD sub- 
types can be broadly placed into two 
types. Type-I vWD is characterized by a 
quantitative defect in plasma vWF, with 
normal vWF multimer structure. Type- 
III vWD is the severe quantitative form of 
vWD with very low or undetectable 
plasma vWF. Type-II vWD variants are 
associated with qualitatively abnormal 
vWF. The molecular genetics of vWD has 
recently been reviewed (Ginsburg and 
Bowie 1992). 
Type-I/III vWD 
Type-I vWD is the most common form, 
accounting for approximately 70%80% 
of all vWD. Type-III vWD is quite rare, 
with a prevalence of 0.5-3 per million 
(Weiss et al. 1982). Though parents of 
type-III vWD patients are generally asymp 
tomatic (recessive inheritance), in some 
cases parents have been observed to have 
mild type-1 vWD. Whether type-1 vWD 
represents the heterozygous form of 
type-III vWD or a distinct genetic disor- 
der is currently unknown. Gross gene 
deletions, nonsense mutations, and a 
frameshift mutation [reviewed by 
Ginsburg and Bowie (1992) and 
Ginsburg and Sadler (1993)] have been 
identified as the molecular defects in a 
limited number of type-III vWD patients. 
Type-IIA vWD 
The most common type-II vWD subtype, 
type IIA, is characterized by selective 
loss of intermediate and HMW multi- 
mers. The bleeding diathesis in type-IL4 
vWD is thought to result from the defi- 
ciency of these larger vWF multimeric 
species, which appear to be most potent 
in mediating platelet adhesion. Recently, 
specific single amino acid substitutions 
have been identified as the molecular 
basis for type-IIA vWD in a large number 
of patients (Ginsburg and Bowie 1992, 
Ginsburg and Sadler 1993). With two 
possible exceptions, all of these muta- 
tions are located within a 134-amino- 
acid segment of the vWF A2 domain 
(Figure 2). Expression of recombinant 
vWF containing type-IL4 vWD mutations 
in heterologous cells suggests that type- 
IIA vWD arises via two distinct molecu- 
lar mechanisms. For one set of muta- 
tions, referred to as group 1, the single 
amino acid substitution results in a 
defect in intracellular transport at the 
level of the ER. Since type-IL4 vWD is 
autosomal dominant, the mutant allele 
is coexpressed with a normal allele. The 
larger the multimer form, the greater is 
the probability of containing one or 
more mutant subunits and the greater is 
the likelihood that it will be retained 
within the ER. Thus, only the smallest 
multimeric species are secreted from the 
cell, accounting for the classic type-IIA 
vWD phenotype (Lyons et al. 1992). In 
group-2 type-IIA vWD, normal vWF mul- 
timeric species are secreted in vitro, but 
are presumably cleaved by one or more 
plasma proteases in vivo, resulting in the 
characteristic loss of large multimers 
(Lyons et al. 1992, Dent et al. 1991). 
Type-IIB vWD 
Type-IIB vWD is also characterized by 
loss of large vWF multimers, but 
through a unique “gain of function” 
mechanism involving increased affinity 
for platelet GpIb. Patients have throm- 
bocytopenia, absence of HMW plasma 
vWF multimers, and significant clinical 
bleeding. Spontaneous binding of the 
most active large type-III3 vWF multi- 
mers to platelets, followed by clearance 
of these complexes from the circulation, 
is thought to result in the characteristic 
type-IIB phenotype. A number of muta- 
tions have been identified in type-III3 
vWD patients, all located within a disul- 
fide bond loop between Cys509 and 
Cys695 in the GpIb-binding region of 
vWF (Figure 2). Four common muta- 
tions account for >90% of the reported 
type-IIB vWD patients (Ginsburg and 
Bowie 1992, Ginsburg and Sadler 1993). 
Factor-VIII-Binding Defects 
A rare group of patients have recently 
been reported with reduced factor VIII 
levels, normal vWF antigen levels and 
activity, normal bleeding time, and a 
bleeding phenotype similar to mild to 
moderate hemophilia A, but with appar- 
ent autosomal recessive inheritance. This 
variant has been termed vWD “Nor- 
mandy” after the birthplace of one of the 
first patients. Mutations within the factor- 
VIII-binding domain of vWF, which abol- 
ish or reduce binding of factor VIII to 
vWF, have now been identified in a 
number of these patients (Mazurier 1992, 
Ginsburg and Sadler 1993, Ginsburg and 
Bowie 1992). These mutations are all 
located within the factor-VIII-binding 
domain at the N terminus of vWF (Fig- 
ure 2). 
l Future Directions 
A great deal has been learned about the 
unique cellular and molecular biology 
of vWF since the first distinction of this 
protein from factor VIII -20 years ago. 
Recently, mutations responsible for many 
of the unique vWD variants have been 
identified. With the characterization of 
additional mutants, it should become 
possible to diagnose and classify vWD 
by using a DNA diagnostic approach. 
Further understanding of the complex 
structure and function of vWF also has 
important implications for the under- 
standing of the regulation of blood 
coagulation. vWF presents a particu- 
larly attractive target for the develop- 
ment of new anticoagulant therapies. 
Elevated vWF levels may be an inde- 
pendent risk factor for coronary-artery 
disease, and vWD has been postulated to 
38 01994, Elsevier Science Inc., lOSO-1738/94/$7.00 TCM Vol. 4, No. 1, 1994 
provide a protective effect (Ginsburg 
and Bowie 1992). Since the moderate 
quantitative decrease in vWF associated 
with the common type-1 variant of vWD 
is generally associated with only a mild 
bleeding disorder, therapies designed to 
disrupt vWF function could be antici- 
pated to have a relatively large thera- 
peutic index and relatively small risks of 
unwanted hemorrhage. Indeed, a num- 
ber of antibody and recombinant pep- 
tide reagents are currently under devel- 
opment as potential new anticoagulants 
(Ruggeri 1992). Thus, the recent explo- 
sion in knowledge about vWF should 
have important clinical impact, not only 
for the care of vWD patients, but for the 
much larger population at risk for pa- 
thologic thrombosis and hemorrhage. 
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